Clinical validation of a serum protein biomarker signature for the early diagnosis of pancreatic cancer.

Informacje na temat projektu

IMMPACT

Identyfikator umowy o grant: 672454

DOI 10.3030/672454

Projekt został zamknięty

Data podpisania przez KE 15 Lipca 2015

Data rozpoczęcia 1 Czerwca 2015

Data zakończenia 31 Maja 2018

Finansowanie w ramach

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Koszt całkowity € 4 244 969,25

Wkład UE € 4 244 969,00

Koordynowany przez

IMMUNOVIA AB
Sweden

Rezultaty

Other (1)

Simplified user interface

Documents, reports (5)

Interim prospective validation report

An interim report will be generated after 18 months into the study to make any necessary adjustments to the study and present the first validation results. This interim report will conclude the requested support from SME-instrument, though the study will continue for yet another 18 months to finalize the study.

Retrospective clinical study report OHSU Study

Retrospective clinical study report OHSU Study retrospective clinical investigation nr 2

Retrospective clinical study report Herlev Study

Retrospective clinical study report Herlev Study retrospective clinical investigation nr 1

Retrospective clinical study report OXFORD Study

Retrospective clinical study report OXFORD Study (retrospective clinical investigation nr 4)

Retrospective clinical study report PANCAN Study

Retrospective clinical study report PANCAN Study (retrospective clinical investigation nr 3)

Websites, patent fillings, videos etc. (1)

Project website